MUMBAI, India, Nov. 21 -- Intellectual Property India has published a patent application (202517099274 A) filed by Inthera Inc., Seoul, Republic of Korea, on Oct. 14, for 'recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor.'
Inventor(s) include Choi, Deog Young; and Jung, Hyun Gyo.
The application for the patent was published on Nov. 21, under issue no. 47/2025.
According to the abstract released by the Intellectual Property India: "The present invention provides a fusion protein for promoting soluble expression of a norovirus antigen, and an expression vector thereof. More specifically, the present invention provides combinations of various genotypes of norovirus antigen proteins and RID mutants, in which the most efficient folding occurs when a norovirus antigen is used as a target protein to form a recombinant fusion protein, the yield of soluble expression of a fusion protein produced is improved, and the assembly efficacy and homogeneity of norovirus VLPs can be enhanced. Also, the present invention provides a method for rapidly mass-producing various other genotypes of norovirus VLPs, as well as GII.4, in E. coli by using mutant RID, thus enabling the development of a VLP-based multivalent vaccine comprising more genotypes."
The patent application was internationally filed on Apr. 12, 2024, under International application No.PCT/KR2024/004954.
Disclaimer: Curated by HT Syndication.
